Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study

Telomir Pharmaceuticals, Inc.

Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.
In a paclitaxel-resistant model, Telomir-1 reduced tumor growth as monotherapy and in combination, and cut cancer cell spread.
Third model (broadly treatment-resistant, ~15-25% of TNBC) showed no significant effect from Telomir-1 or paclitaxel.
Responsive models represent ~40-60% of TNBC; company plans patient selection based on tumor biology for future trials.
Study used BioReperia’s ZTX ONCOLEADS platform; company continues IND-enabling activities.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.